KDRA to withdraw discontinuation of government's R&D new drug assistance program

Published: 2003-03-18 06:59:00

Updated: 2003-03-18 06:59:00

The Korea Drug Research Association presented to the Ministry of Health and Welfare a written petition related to the outstanding five industry recommendations on March 12, requesting that the ministry withdraw its policy to discontinue a new R&D funding program to domestic pharmaceutical industr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK